S&P Futures
5,899.75 +3.25 (+0.06%) Dow Futures
43,476.00 -92.00 (-0.21%) Nasdaq Futures
20,562.75 +69.00 (+0.34%) Russell 2000 Futures
2,320.60 +7.00 (+0.30%) Crude Oil
67.31 +0.29 (+0.43%) Gold
2,595.20 +25.10 (+0.98%)
Evaxion Biotech A/S (EVAX)
After hours:
| Previous Close | 1.6800 |
| Open | 1.6300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.4000 - 1.6800 |
| 52 Week Range | 1.4000 - 13.6100 |
| Volume | |
| Avg. Volume | 51,810 |
| Market Cap | 8.032M |
| Beta (5Y Monthly) | -0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8000 |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.56 |
GlobeNewswireEvaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq’s equity requirementEvaxion remain committed to ensuring compliance and maintain our Nasdaq listing COPENHAGEN, Denmark, November 13, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has, as antici
- Zacks Small Cap Research
EVAX Racks up Positive Test Results
By Brad Sorensen, CFA NASDAQ:EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it
